Burimamide
From Wikipedia, the free encyclopedia
| Names | |
|---|---|
| IUPAC name
1-[4-(1H-imidazol-5-yl)butyl]-3-methylthiourea | |
| Identifiers | |
3D model (JSmol) |
|
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| Properties | |
| C9H16N4S | |
| Molar mass | 212.32 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25°C [77°F], 100kPa).
| |
Chemical compound
Burimamide is an antagonist at the H2 and H3 histamine receptors. At physiological pH, it is largely inactive as an H2 antagonist,[1] but its H3 affinity is 100x higher. It is a thiourea derivative.
Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers.[2] The discovery of burimamide ultimately led to the development of cimetidine (Tagamet).[2]
See also
[edit ]References
[edit ]- ↑ Clayden, Jonathan; Greeves, Nick; Warren, Stuart; Wothers, Peter (2001). Organic Chemistry (1st ed.). Oxford University Press. p. 205. ISBN 978-0-19-850346-0.
- 1 2 2</sub>-receptor Antagonists"},"publisher":{"wt":"American Chemical Society"},"work":{"wt":"National Historic Chemical Landmarks"},"access-date":{"wt":"June 25, 2012"},"url-status":{"wt":"dead"},"archive-url":{"wt":"https://archive.today/20121209003707/http://portal.acs.org/portal/PublicWebSite/education/whatischemistry/landmarks/cimetidinetagamet/"},"archive-date":{"wt":"December 9, 2012"}},"i":0}}]}'/>"Tagamet: Discovery of Histamine H2-receptor Antagonists". National Historic Chemical Landmarks. American Chemical Society. Retrieved June 25, 2012.
{{cite web}}: CS1 maint: deprecated archival service (link)
Stub icon
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by adding missing information.